Whitehawk Therapeutics Q3 net loss widens on R&D expenses

Overview

• US oncology therapeutics firm's Q3 net loss widened, missing analyst expectations

• Q3 operating income and pretax loss also missed analyst estimates

• Company advanced all three ADC programs into clinical development, HWK-206 received FDA Fast Track

Outlook

• Company expects initial Phase 1 data from HWK-007 and HWK-016 in 1H 2027

• Initial Phase 1 data from HWK-206 expected by year-end 2027

• Cash position anticipated to fund operations into 2H 2028

Result Drivers

• R&D SPENDING - Research and development expenses rose to $18.1 mln in Q3 from $14.3 mln a year earlier as co advanced three ADC programs in clinical development

• CLINICAL TRIAL ADVANCEMENTS - Co initiated Phase 1 trial for HWK-206 and continued dose escalation in HWK-007 and HWK-016 programs

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Whitehawk Therapeutics, Inc. is $8.00, about 155.6% above its November 6 closing price of $3.13

Reuters Recommended Reads

• Nov 6 - CG Oncology Q3 net loss widens on higher R&D costs

• Nov 9 - Aura Biosciences Q3 net loss widens on higher R&D and restructuring costs

• Nov 6 - UK's Immunocore Q3 loss misses estimates on higher R&D spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)